Clinical Trial Update: Zanidatamab Combined With Chemotherapy as Neoadjuvant Therapy for HER2-high Expression G/GEJC [Phase 2]

View source ↗

Summary

A Phase 2 neoadjuvant trial is evaluating Zanidatamab in combination with chemotherapy for HER2-high gastric/gastroesophageal junction adenocarcinoma; the study…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Cancer
• Gastroesophageal Junction Adenocarcinoma

Drugs mentioned

• Zanidatamab

Snippet

Sponsor: Xijing Hospital | Conditions: Gastric/Gastroesophageal Junction Adenocarcinoma | Phase 2 | Status: NOT_YET_RECRUITING